In a wide-ranging discussion, the two leaders touched upon vaccine development, infant mortality, US education, research funding, machine learning, and precision medicine.
The award will support the development of diagnostics and analytical tools for childhood disease detection using tissue-based fluorescent in situ sequencing.
The company is currently in discussions with several investor groups and plans to use the funds to expand the reach of the test and prepare for FDA submission.
Intended for diagnosing active pulmonary tuberculosis, the test will use Cere's Nanotrap reagents for enriching target analytes for downstream analysis.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
